A Study to Evaluate Solrikitug in Participants With COPD (ZION)

Summary

A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start

2024-08-14

Primary completion

2026-06-30

Completion

2026-10-31

Drugs

Indications